NEW YORK, NY--(Marketwired - Jun 18, 2013) - Nuvilex, Inc.'s (
Medical Marijuana Sciences will initially utilize cannabidiol, one of the compounds found in Cannabis, as the basis for developing treatments for some of the deadliest forms of cancer that have historically shown they're extremely difficult to treat. Meanwhile other groups are finding success initiating research using cannabis for epilepsy, heart damage, and traumatic brain injuries.
In a new animal study found in the journals Behavioral Brain Research and Experimental Brain Research, the study's author suggests that marijuana could act as a type of vaccine protecting the brain from future traumatic brain injuries. Dr. Yosef Sarne, of the Adelson Center for the Biology of Addictive Diseases at Tel Aviv University, authored the study and theorizes that ultra-low doses of tetrahydrocannabinol or THC -- the main psychoactive component of marijuana -- induces minor damage to the brain, which may actually "precondition" the brain to protect it against more severe damage from injuries such as hypoxia (lack of oxygen), seizures or toxic drug exposure.
In Dr. Sarne's prior studies, mice were injected with higher doses of THC around 30 minutes before or after incurring a brain injury.
Continue reading this article at www.stockmarketmediagroup.com/features.
About Stock Market Media Group
Stock Market Media Group, formerly Stock House Group, is a full service Investment Relations firm specializing in Research, Content Development and Awareness. The firm offers a platform for CEOs to tell their story through the media with its Feature Articles, Research Reports, and CEO Interviews. At the same time, the company is building a library of Research on its website for Investors to become better informed on small cap stocks. For more information: www.stockmarketmediagroup.com